Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)염증이 고조된 SARS-CoV-2 관련 심근 손상에서 심장 및 호흡 기능의 악화를 감소시키는 카나키누맙(Covid-19 심장 손상에서의 카나키누맙: 3개의 C 연구)Trial Designs Published on 2020-08-242022-09-10 Journal: Clinical Cardiology [Category] MERS, SARS, 바이오마커, 임상, 진단, [키워드] anticipated baseline characteristics C‐reactive protein canakinumab cardiac cardiac injury Characteristics Controlled trial COVID‐19 CRP defined Deterioration discharge dysfunction elevated Elevation elevations enrolled evaluate hospital Hospitalized hospitalized COVID‐19 patients hyperlipidemia hypertension Hypothesis IMPROVE Inflammation male median morbidity morbidity and mortality Mortality myocardial injury occur Ordinal Scale outcome Patient Placebo Prevalence Prevent primary endpoint progressive respiratory failure randomization Randomized controlled trial randomized patient reduce Respiratory failure Respiratory function Result SARS‐CoV‐2 SARS‑CoV2 SARS‐CoV2 infection SARS‐CoV‐2 secondary endpoint Seven Time to recovery Treatment troponin troponin T worsening [DOI] 10.1002/clc.23451 PMC 바로가기 [Article Type] Trial Designs
Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heartArticle Published on 2020-08-012023-06-16 Journal: Cardiovascular Research [Category] MERS, [키워드] ACE2 cardiac injury COVID-19 SARS-CoV-2 TMPRSS2 [DOI] 10.1093/cvr/cvaa191 PMC 바로가기
D-dimer surge and coagulation disorders in COVID-19 related pneumonia patients with cardiac injury A case series4800 Published on 2020-07-312022-10-30 Journal: Medicine [Category] COVID-19, SARS, [키워드] accompanied analyzed cardiac injury Case series case sery cause Cerebrovascular disease cerebrovascular diseases changes in characterized clinical clinical trial coagulation disorder coagulation disorders coagulation parameter collected COVID-19 COVID-19 patient criteria D-dimer D-dimer level D-dimer surge death defined disorder fibrinogen FIVE five COVID-19 patient higher risk Hospitalization Hypothesis In-hospital In-hospital death incubated Injury invasive ventilation management outcome Patient patients patients died Platelet Pneumonia Prothrombin time rapid increase reached reduced Registered Retrospective study severe coronavirus disease Support upper reference limit [DOI] 10.1097/MD.0000000000021513 PMC 바로가기 [Article Type] 4800
Lesão Miocárdica na COVID-19: Um Desafio para o Cardiologista ClínicoImagem Published on 2020-07-282022-10-28 Journal: Arquivos Brasileiros de Cardiologia [Category] Coronavirus, SARS, [키워드] cardiac injury cardiovascular diseases chest pain coronavirus COVID-19 Doenças Cardiovasculares Dor torácica Lesão Cardíaca Miocardite myocarditis Pandemia pandemic [DOI] 10.36660/abc.20200434 PMC 바로가기 [Article Type] Imagem
Cardiac injury associated with severe disease or ICU admission and death in hospitalized patients with COVID-19: a meta-analysis and systematic reviewResearch Published on 2020-07-282022-11-01 Journal: Critical Care [Category] COVID-19, [키워드] 95% CI Abstract Admission Analysis arrhythmia article Biomarker Biomarkers cardiac injury Chinese CK-MB CNKI Cochrane Library coronavirus disease COVID-19 COVID-19 patient database death elevated higher risk hospitalized patient ICU ICU admission IL-6 IL-6 level IL-6 levels independent predictor individuals Infrastructure Injury intensive care interleukin-6 investigator investigators lactate dehydrogenase LDH medRxiv Meta-analysis Mortality Myocardial Patient Prognosis proportion Result risk searched severe disease significantly higher significantly increased systematic review TnI troponin I [DOI] 10.1186/s13054-020-03183-z PMC 바로가기 [Article Type] Research
Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learnedCOVID-19 및 심혈관 부담에 대한 항말라리아 및 세포독성 약물: 문헌 검토 및 배울 교훈Review Published on 2020-07-212022-09-10 Journal: Vascular [Category] MERS, SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adverse drug reaction Adverse drug reactions antiviral activity Azithromycin best bleeding cardiac cardiac injury cardiovascular burden Chloroquine clinical evidence clinical trial clinical trials coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated disorder drug Endothelial dysfunction Evidence evidence of focus Google Scholar Guidance Hospitalized hospitalized patients Hydroxychloroquine hydroxychloroquine plus azithromycin in vitro increasingly Injury literature literature review Neuropathology Patient care Remdesivir reported resource Result review severe acute respiratory syndrome Coronavirus stroke systemic inflammation thrombosis thrombotic thrombotic microangiopathy was performed [DOI] 10.1177/1708538120941635 PMC 바로가기 [Article Type] Review
COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network코로나19와 고혈압 근거와 실천: HOPE Asia Network의 안내Review Published on 2020-07-012022-09-11 Journal: Journal of clinical hypertension (Greenwich, Conn. [Category] SARS, 바이오마커, [키워드] acute respiratory distress acute respiratory distress syndrome addition adverse outcome adverse outcomes age angiotensin Angiotensin receptor blockers Angiotensin-converting enzyme angiotensin-converting enzyme 2 angiotensin-converting enzyme 2 receptors angiotensin-converting enzyme inhibitors antihypertensive therapy Asia best Biomarker Biomarkers blood pressure can be used cardiac injury cells Complication coronavirus coronavirus 2019 disease Course COVID-19 creatinine cytokine Cytokine storm D-dimer develop Evidence facilitate Factor Health status heart failure help home blood pressure monitoring hypertension include increase independent independent of Infection inhibitor Kidney injury maintain maintenance management MONITOR myocardial injury N-terminal N-terminal pro-B-type natriuretic peptide network new infection Other outcome pandemic Patient Patient management patients patients with COVID-19 peptide poor prognosis pro-B-type natriuretic peptide Psychological well-being RAS RAS inhibitor RAS inhibitors receptor regular exercise Renin renin-angiotensin system respiratory distress Respiratory distress syndrome resulting risk risk factor Risk factors risk stratification SARS-CoV-2 virus SARS-CoV-2 virus infection serum creatinine severe COVID-19 social distancing syndrome Telemedicine the SARS-CoV-2 virus thrombosis troponin virus infection [DOI] 10.1111/jch.13917 PMC 바로가기 [Article Type] Review
The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysisMeta-Analysis Published on 2020-07-012023-07-14 Journal: Progress in Cardiovascular Diseases [Category] SARS, [키워드] cardiac injury coronavirus COVID-19 Mortality [DOI] 10.1016/j.pcad.2020.04.008 PMC 바로가기 [Article Type] Meta-Analysis
COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivorsArticle Published on 2020-06-262023-07-01 Journal: Heart Rhythm [Category] SARS, [키워드] arrhythmia cardiac injury Cardiomyopathy COVID-19 myocarditis [DOI] 10.1016/j.hrthm.2020.06.026 PMC 바로가기
Cardiovascular manifestations in severe and critical patients with COVID ‐19Clinical Investigations Published on 2020-06-202022-10-31 Journal: Clinical Cardiology [Category] COVID-19, [키워드] acute respiratory syndrome Admission analyzed arrythmia Atrial fibrillation blood pressure bradycardia cardiac function cardiac injury cardiac marker cardiovascular Cardiovascular manifestations cardiovascular system Clinical outcome Corona coronavirus COVID COVID‐19 COVID‐19 infection COVID‐19 patient COVID‐19 Critical Critical case critical cases critical status D‐dimer diabetes diagnosed enrolled Factor FIVE heart failure Hospitalization Hypotension independent risk factor Infection Inflammatory Intervention less male manifestation monitoring myocardial injury occurred Occurrence organ Patient patients Pneumonia Result SARS‐CoV‐2 Seven Severe case Severe patient severity significantly higher Sinus tachycardia suffered systemically Tachycardia TnI Treatment troponin ventricular virulent vital sign [DOI] 10.1002/clc.23384 PMC 바로가기 [Article Type] Clinical Investigations